These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 719130)

  • 1. Daunorubicin, daunorubicinol and DNA plasma kinetics after I.V. administration of daunorubican-DNA complex in the rabbit.
    Hulhoven R
    Biomedicine; 1978 Jul; 29(5):164-7. PubMed ID: 719130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daunorubicin, daunorubicinol and DNA plasma kinetics after I.V. administration of daunorubicin-DNA complex in the rabbit. II. -- Effects of R. E. S.-blockade.
    Hulhoven R; Haravengt C
    Biomedicine; 1980 Apr; 33(2):44-7. PubMed ID: 7407324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of daunorubicinol in the rabbit: comparison with daunorubicin.
    Maniez-Devos DM; Baurain R; Trouet A; Lesne M
    J Pharmacol; 1986; 17(1):14-20. PubMed ID: 3713197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation.
    Maniez-Devos DM; Baurain R; Lesne M; Trouet A
    J Pharmacol; 1986; 17(1):1-13. PubMed ID: 3713196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPLC determination of daunorubicin and daunorubicinol in human plasma.
    Hulhoven R; Desager JP
    Biomedicine; 1977 Apr; 27(3):102-4. PubMed ID: 890014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat.
    Cusack BJ; Young SP; Vestal RE; Olson RD
    Cancer Chemother Pharmacol; 1997; 39(6):505-12. PubMed ID: 9118462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and plasma kinetics of daunorubicin given by two methods of administration in a patient with acute leukemia.
    DeGregorio MW; Carrera CJ; Klock JC; Pegelow CH; Wilbur JR
    Cancer Treat Rep; 1982 Dec; 66(12):2085-8. PubMed ID: 6958366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex.
    Andersson B; Andersson I; Beran M; Ehrsson H; Eksborg S
    Cancer Chemother Pharmacol; 1979; 2(1):15-7. PubMed ID: 498413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat.
    Cusack BJ; Young SP; Olson RD
    Cancer Chemother Pharmacol; 1995; 35(3):213-8. PubMed ID: 7805179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy.
    Gessner T; Preisler HD; Azarnia N; Bolanowska W; Vogler WR; Grunwald H; Joyce R; Goldberg J
    Med Oncol Tumor Pharmacother; 1987; 4(1):23-31. PubMed ID: 3600054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients.
    Eksborg S; Ehrsson H; Andersson B; Beran M
    J Chromatogr; 1978 Jun; 153(1):211-8. PubMed ID: 659557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic study of intravenous and oral idarubicin in cancer patients.
    Tamassia V; Pacciarini MA; Moro E; Piazza E; Vago G; Libretti A
    Int J Clin Pharmacol Res; 1987; 7(5):419-26. PubMed ID: 3478310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of daunorubicin intravenously injected or intravenously infused as free drug and as a complex with DNA in rabbits.
    Hulhoven R; Harvengt C
    Pharmacology; 1982; 24(4):253-60. PubMed ID: 7089047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
    Jaenke RS; Deprez-DeCampeneere D; Trouet A
    Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979).
    Callies S; de Alwis DP; Mehta A; Burgess M; Aarons L
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):39-48. PubMed ID: 15045528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic disposition of 5-iminodaunorubicin in the rat.
    Peters JH; Gordon GR; Kashiwase D; Acton EM
    Cancer Res; 1984 Apr; 44(4):1453-9. PubMed ID: 6704961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
    Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
    Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia.
    Paul C; Liliemark J; Tidefelt U; Gahrton G; Peterson C
    Ther Drug Monit; 1989; 11(2):140-8. PubMed ID: 2718219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography.
    Andrews PA; Brenner DE; Chou FT; Kubo H; Bachur NR
    Drug Metab Dispos; 1980; 8(3):152-6. PubMed ID: 6104578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.
    Zucchetti M; Boiardi A; Silvani A; Parisi I; Piccolrovazzi S; D'Incalci M
    Cancer Chemother Pharmacol; 1999; 44(2):173-6. PubMed ID: 10412954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.